Background: Prostate Imaging-Reporting and Data System v. 2 (PI-RADSv2) provides standardized nomenclature for interpretation of prostate multiparametric MRI (mpMRI). Inclusion of additional features for categorization may provide benefit to stratification of disease. Purpose: To prospectively compare PI-RADSv2 to a qualitative in-house system for detecting prostate cancer on mpMRI. Assessment: One genitourinary radiologist prospectively read mpMRIs using both in-house and PI-RADSv2 5-category systems. Statistical Test: In lesion-based analysis, overall and clinically significant (CS) tumor detection rates (TDR) were calculated for all PI-RADSv2 and in-house categories. The ability of each scoring system to detect cancer was assessed by area under receiver operator characteristic curve (AUC). Within each PI-RADSv2 category, lesions were further stratified by their in-house categories to determine if TDRs can be increased by combining features of both systems. Results: In 338 patients (median prostate-specific antigen [PSA] 6.5 [0.6-113.6] ng/mL; age 64 [44-84] years), 733 lesions were identified (47% tumor-positive). Predictive abilities of both systems were comparable for all (AUC 76-78%) and CS cancers (AUCs 79%). The in-house system had higher overall and CS TDRs than PI-RADSv2 for categories 3 and 4 (P < 0.01 for both), with the greatest difference between the scoring systems seen in lesions scored category 4 (CS TDRs: in-house 65%, PI-RADSv2 22.1%). For lesions categorized as PI-RADSv2 5 4, characterization of suspicious/indeterminate extraprostatic extension (EPE) and equivocal findings across all mpMRI sequences contributed to significantly different TDRs for both systems (TDR range 19-75%, P < 0.05).
Data Conclusion: PI-RADSv2 behaves similarly to an existing validated system that relies on the number of sequences on which a lesion is seen. This prospective evaluation suggests that sequence positivity and suspicion of EPE can enhance PI-RADSv2 category 4 A s multiparametric magnetic resonance imaging (mpMRI) has become more widespread, there is an increasing demand for standardization of image acquisition and interpretation. [1] [2] [3] The Prostate Imaging-Reporting and Data System v. 2 (PI-RADSv2) utilizes a dominant sequence strategy in each zone, with a final lesion-based category assignment ranging from 1-5 representing low to high likelihood of cancer. 5 In the peripheral zone (PZ), diffusionweighted imaging (DWI) is considered dominant and there is secondary assistance from dynamic contrast-enhanced (DCE) MRI. In the transition zone (TZ) T 2 -weighted (T 2 W) imaging is dominant, with limited support from DWI characteristics. These recommendations are largely based on expert consensus and data supporting zone-specific dominant sequence differentiation is limited. 6, 7 Furthermore, the subjective nature of interpretation within the PIRADSv2 lexicon may contribute to high interreader variability reported in early validation studies. 8, 9 For several years prior to PI-RADSv2, we had successfully used a simple in-house scoring system for prostate MRI that was mostly based on the number of sequences on mpMRI that were positive. Recognizing the benefits of using a standardized nomenclature and diagnostic criteria, we rapidly adopted PI-RADSv2 but continued using the inhouse scoring system to ease the transition with our referring clinicians who had less familiarity with the new system. Our purpose is to prospectively compare the performance of these two systems in the hopes of finding features in the older system that could be used to improve the performance of PI-RADSv2 as we consider the next version of this scoring system. 8, [11] [12] [13] 
Materials and Methods

Study Population
This single-institution prospective Health Insurance Portability and Accountability Act (HIPAA)-compliant study was approved by the local Institutional Review Board. All patients gave written informed consent before undergoing mpMRI (T 2 W, DWI [ADC map, b-2000 DWI acquisition], and DCE MRI) at 3T. PI-RADSv2 became available in January of 2015. Beginning May 2015 to May 2016, 963 consecutive patients underwent mpMRI at our institution. Of these patients, 364 underwent MRI/transrectal ultrasound (TRUS) fusion-guided biopsy. Inclusion criteria were having mpMRI at 3T with subsequent MRI/TRUS fusion biopsy. Patients were excluded for not having subsequent MRI/TRUS fusion-guided biopsy (n 5 599), for receiving a prior treatment (n 5 25), or for missing prospective categorization with the inhouse system (n 5 1); 338 patients were included in the final study population. The patient population in this study is part of a large prospective PI-RADSv2 validation study population. Previous reports on this group include establishing the correlation of PIRADSv2 scoring system with the International Society of Urological Pathology (ISUP) Prostate Cancer Grade Group System. 14 Here we report a prospective comparison of PI-RADSv2 and an in-house method of MRI interpretation.
MRI Technique
mpMRIs were obtained at 3T (Achieva 3.0T-TX, Phillips Healthcare, Best, Netherlands) either using an endorectal coil (BPX-30, Medrad, Pittsburgh, PA) with anterior half of a 32-channel cardiac SENSE coil (InVivo, Gainesville, FL), or using only the 32-channel cardiac SENSE coil. The endorectal coil was filled with 45 mL Fluorinert (3M, Maplewood, MN), and was utilized in the majority of the patients. The mpMRI protocol included T 2 W (axial, coronal, sagittal), DWI (up to b-2000 mm/sec 2 with endorectal coil, up to b-1500 mm/sec 2 without endorectal coil) available as an ADC map and high b-value sequence, and DCE MRI and is summarized in Table 1 .
MRI Interpretation
All MRI scans were read by one highly experienced genitourinary radiologist (B.T.) (6000 scans read from 2007-2015), with suspicious lesions identified prospectively as part of the clinical workflow. Suspicious areas were categorized using the 2015 PI-RADSv2 guidelines and simultaneously categorized using the traditional qualitative in-house system in use since 2007. Both systems are 5-category systems. PI-RADSv2 categorization is based on specific descriptions of lesion appearance that are incorporated into a zonebased schema, as illustrated in Table 2 . 15 The in-house system relies on the number of sequences on which the lesion can be identified plus 1 point for possible extraprostatic extension (EPE) and 2 points for definite EPE. 1, 12 The in-house system guidelines are given in Table 3 .
Reference Standard
Patients with suspicious lesions identified on mpMRI were recommended for subsequent MRI/TRUS fusion-guided biopsy. All biopsies were performed using the office-based UroNav platform (InVivo) with prepared lesion targets. Each lesion was sampled with two cores: one in the axial plane and the other in the sagittal plane. All procedures were performed by either one urologist (P.A.P.) or by one interventional radiologist (B.J.W.), both of whom had performed >1500 MRI/TRUS fusion-guided biopsies at the time of the study. One genitourinary pathologist (M.J.M.) (>25 years of experience in interpretation of prostate histopathology) analyzed the resultant biopsy cores, with primary and secondary Gleason scores 
Statistical Analysis
Tumor detection rate (TDR), defined as the proportion of truepositive lesions among all detected lesions, was calculated for each category within the PI-RADSv2 and in-house scoring systems. The standard error (SE) and 95% confidence interval (CI) of TDRs were calculated from 2000 bootstrap samples by a random sampling of patients with replacement. The 95% CIs were obtained from the 2.5% and 97.5% percentiles of the bootstrap resampling distribution. The significance of the difference in TDRs between PI-RADSv2 and in-house systems was evaluated at each category level (1-5) using the Wald test. To partially account for multiple testing, a more conservative significance level of 0.01 was used. The ability of each scoring system to detect cancer was assessed by receiver operator characteristic (ROC) curve analysis, Final in-house category T2W DWI DCE Extraprostatic extension
Minimal capsular bulge and/or lesion capsule contact length 1.5 cm
Baseline sequence-based detection positivity and negativity is established, and cumulative result produces final categorization 1-5.
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evaluated for all cancers and clinically significant cancers. Area under the curve (AUC) was reported for each system. SE and 95% CIs were calculated using the same bootstrap resampling technique described above.
Within each PI-RADSv2 category, lesions were further stratified by the assigned in-house category for that patient to compare TDRs across concordant and discordant categorization across the two systems. The difference in TDR across consecutive in-house categories within each PI-RADSv2 category was tested using the Wald test based on the boostrap standard error (2,000 samples by random sampling of patients with replacement). All P-values correspond to two-sided tests, with P < 0.05 considered to represent a significant difference.
Results
Patient and Lesion Characteristics
The final study population consisted of 338 patients. The median prostate-specific antigen (PSA) was 6.5 (range 0.6-113.6) ng/mL and median age was 64 (44-84) years. The median time between MRI and MRI/TRUS fusion-guided biopsy was 36 (0-241) days.
A total of 733 lesions were detected and categorized on mpMRI with subsequent MRI/TRUS fusion-guided biopsy, of which 346/733 (47%) were histopathologically proven tumor-positive (n 5 110, 120, 45, 54, 17 were Gleason 3 1 3, 3 1 4, 4 1 3, 4 1 4, 4 1 5, respectively).
Cancer Detection Performance
Performance of both systems for detecting cancer is shown for all disease and CS disease in Fig. 1 . The in-house system showed a nonsignificant benefit to overall cancer detection compared to PI-RADSv2, with AUC 77.6% and 76.2%, respectively (P 5 0.20). Both systems demonstrated the ability to locate CS cancer, with AUCs of 0.78 and 0.79 for PI-RADSV2 and the in-house system, respectively (P 5 0.45).
Lesion-based scoring of the two systems is compared in Table 4 . Category 5 showed the highest concordance Fig. 2 . The category with the lowest concordance in scoring between the systems (category 4) also demonstrated the greatest difference in tumor detection rates for all cancers (PI-RADSv2 TDR: 39.6%, in-house TDR: 78.3%, P < 0.0001) ( Fig. 2A) . This pattern remained consistent in detection rates for CS cancer (PI-RADSv2 CS TDR: 22.1%, in-house CS TDR: 65%, P < 0.0001) (Fig. 2B) .
Substratification of PI-RADSv2 Category Assignment
Given the similar overall performance between the two systems, we attempted to determine whether PI-RADSv2 scored lesions could be substratified by their in-house score. For instance, lesions assigned PI-RADSv2 5 3, 4, or 5 were substratified by the in-house scoring system (Fig. 3) . In all cases, lesions with fewer positive findings on mpMRI sequences demonstrated poorer TDR. The greatest differences were seen in lesions classified as PI-RADSv2 category 4, with 75% all cancer TDR in lesions positive on all three sequences and suspicious for EPE (in-house category 4 or higher) compared to 41.3% for all cancer TDR in lesions positive on all three sequences without EPE (in-house category 3) and 19.4% all cancer TDR in lesions positive on only two sequences (in-house category 2), P 5 0.048 and P 5 0.014, respectively (Fig. 3A) . Similar trends were noted for detection of clinically significant disease (Fig. 3B) , demonstrating CS TDR was lowest in PI-RADSv2 category 4 lesions positive only on two sequences (in-house category 2), P 5 0.0002 (Fig. 3B) . Lesions scored PI-RADSv2 category 5 substratified by definite EPE (in-house category 5), suspicious EPE (in-house category 4), and no EPE (in-house category 3) also showed differences in all cancer TDR (95.3%, 7.8%, 55.0%, respectively) and CS TDR (80.3%, 67.3%, 35.0%). Examples of two PI-RADSv2 category 4 lesions with different in-house categorization are shown in Fig. 4 .
Discussion
The ideal categorization system for MRI-detected prostate lesions would rank the likelihood of detecting clinically significant cancer according to each stepwise increase in score, with the highest category achieving the highest detection rates for CS disease. This study demonstrates that PIRADSv2 performed fairly well in this regard, achieving an overall AUC of 0.79 for CS cancer. This compares favorably with another scoring system previously validated at our institution that relied on completely different criteria, suggesting that future versions of PI-RADSv2 might benefit from integrating features from other scoring systems. Prior comparisons of in-house qualitative systems to PIRADSv1 demonstrated poorer performance of PI-RADSv1. 6 In the present study, PI-RADSv2 performed comparably to an in-house system, suggesting that PI-RADSv2 is a marked improvement over the prior version. Our results are in broad agreement with detection AUCs reported for PI-RADSv2 in other studies, which range from 60.2-88%. 16, 17 Collectively, these affirm the diagnostic value of PI-RADSv2. As one might expect, scoring systems tend to perform better for larger and more obvious lesions. For instance, lesions graded category 5 by either PI-RADSv2 or the inhouse system achieved the highest tumor detection rates (>70% for all cancers, >80% for CS cancer). Definite EPE at mpMRI, a key component of both systems' categorization to 5 has been linked to detection of CS prostate cancer, higher Gleason scores, and more extensive disease. [18] [19] [20] However, PI-RADSv2 does not incorporate varying degrees of confidence in the diagnosis of EPE, whereas the in-house system assigns 1 extra point for mild EPE and 2 points for definite EPE. We found that adding this feature to PIRADSv2 category 4 lesions allowed for useful stratification It is generally acknowledged that the CS tumor detection rate for PI-RADSv2 category 4 has been lower than originally expected. 5, 9, [25] [26] [27] This may be partly due to upgrading of category 3 lesions to 4 based on one of several rules included in PI-RADSv2. Lesions in the PZ with equivocal DWI findings but positive enhancement on DCE MRI are upgraded to category 4, and similarly TZ lesions with equivocal T 2 W MRI findings but definite positive DWI findings can be upgraded to PI-RADSv2 category 4. It has been documented that the cancer detection rate (CDR) for upgraded (3 1 1) category 4 lesions is lower than pure category 4 lesions, 28 and the addition of 3 1 1 lesions tends to bring down the overall CDR for category 4. Unlike PI-RADS, the in-house system reserves category 4 status for "absolute positive" findings in all three MR pulse sequences with at least one aggressive feature such as suspicious EPE. Applying additional features of suspicious but not necessarily definite EPE criteria to PI-RADSv2 category 4 lesions appears to substratify lesions categorized as PI-RADSv2 5 4 into a higher-risk subset. Our study utilized a single reader in testing detection rates for the two categorization systems. We have previously published on interobserver agreement across five readers for both systems and found reasonably comparable agreement for overall suspicion score assigned by the in-house system (kappa 5 0.55) versus PI-RADSv2 (kappa 5 0.46). 8 Furthermore, in broad agreement with this study, we found that an increase in suspicion score correlated with more clinically significant disease. However, the prior study was a retrospective PI-RADSv2 evaluation, and the present study benefits from prospective reading by an expert familiar with both systems. Additionally, the secondary objective in this prospective study was understanding the features that do not overlap between the two scoring paradigms. Utilization of an expert reader provides an opportunity to identify differences that can further contribute to stratification of disease. Additional limitations of the study include that the inhouse system has been in use at our institution for mpMRI interpretation for 10 years, while PI-RADSv2-based interpretation began with its release in 2015. We did allow for a 3-month lead-in to gain experience with PI-RADSv2 before beginning accrual to this study. Nonetheless, it is difficult to isolate the advantage that familiarity with the in-house system provides. It is important to note, however, that our PIRADSv2 TDRs are in broad agreement with other recent PI-RADSv2 validation data.
14 Finally, our study cohort consisted of patients who underwent MRI/TRUS fusion-guided biopsy, which is inherently a limited gold standard compared to a radical prostatectomy population. The biopsy system utilized in this study has been proven to have accuracy of within 3 mm of lesion targets. 35 However, while radical prostatectomy-based histopathology is a more definitive ground truth, the surgical population is biased towards higher-grade disease and not necessarily representative of a typical screening population of at-risk patients undergoing mpMRI for diagnosis for which the scoring systems were designed.
In conclusion, PI-RADSv2 performed comparably to an existing validated in-house scoring system in use for over Journal of Magnetic Resonance Imaging 10 years. Further analysis of PI-RADSv2 categories 4 and 5 lesions reveals that when features of the in-house system were integrated into PI-RADSv2, substratification into higher-and lower-risk patients was achieved within each PIRADSv2 score. Such features include the number of positive MRI sequences and the degree of suspected EPE. These findings should inform future iterations of PI-RADS.
